In the NeoALTTO phase 3 trial, involving 180 patients with HER2+ BC, intratumor CD36 gene expression was identified as a predictor of worse clinical outcomes in early-stage HER2+ BC treated with trastuzumab-based neoadjuvant therapy [213]. This evidence concerns the gene CD36 and breast cancer.